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A BST R AC T   
 
Aim: To investigate the levels of metabolites (predominantly uric acid) effective on biochemical, and 
coagulation parameters and evaluate their effects on the onset, and course of the disease. 
Methods: In this retrospective study, files of 92 patients hospitalized between January 2007, and 
December 2013, in our clinic with established diagnosis of sudden hearing loss were screened. The 
biochemical (predominantly uric acid), and hematological parameters were compared with those of 
the control group. In addition, the patient group was divided into two groups according to uric acid 
levels and the difference between the groups was investigated in terms of the onset or course of the 
disease. 
Results: A significant difference was not detected between the patient, and the control groups 
regarding mean uric acid levels. Among biochemical parameters glucose, creatinine, and international 
normalized ratio (INR) were significantly higher (p<0.05) while a significant intergroup difference 
was not detected as for other parameters. A significant intergroup difference was not detected in mean 
pure- tone averages, and mean hearing gain at admission between two groups formed based on uric 
acid levels, while post-treatment pure-tone average was significantly better in patients with higher 
serum uric acid levels. In the patient group, uric acid levels were significantly higher in patients with 
partial hearing loss relative to those with total loss.  
Conclusion: In our study, we could not find a significant difference between the patient and the 
control groups as for uric acid levels. However, we have encountered evidence supporting the 
possible role of serum uric acid levels in the prognosis of sudden hearing loss.  
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Introduction 
“Sudden Hearing Loss” (SHL) is defined as 
development of sensorineural hearing loss 
(SNHL) of at least 30 dB at three contiguous 
frequencies within less than 72 hours [1]. 
Although its etiology has not been clarified 
definitively, vascular theory is the most 
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accepted one [2]. Cochlear perfusion with 
terminal arteries, and its higher sensitivity to 
hypoxia tend to support vascular injury as an 
etiologic factor. Available evidence indicates 
that metabolic diseases with microvascular 
effects such as diabetes, and hyperlipidemia are 
effective in the development of SHL [3]. Still, 
SHL secondary to neurological damage due to 
viral, neurotoxic, traumatic etiologies can be 
also seen [1]. 
Uric acid is the end-product of purine 
metabolism, and its levels increase in line with 
oxidative stress. In various studies performed, 
increased levels of uric acid have been 
indicated in conditions developed in association 
with vascular pathologies as myocardial 
infarction, and cerebrovascular events, and also 
its close association with endothelial 
dysfunction has been reported [4]. However in 
a few studies performed in recent years, 
correlations between lower uric acid levels, and 
increasing prevalence, and deteriorated course 
of some neurological diseases as Parkinson’s 
disease, and Alzheimer’s disease have been 
detected [5]. 
This trial aims to investigate the role of uric 
acid in the etiology, and prognosis of SHL. 
Together with uric acid, other metabolites and 
blood level parameters that might affect plasma 
have been analyzed. 
 
Materials and Methods 
The study was performed after obtaining 
approval of the ethics committee of the faculty 
(Decision #17522305/678). File numbers of the 
inpatients treated in our ENT service between 
January 2007 and December 2013 were 
acquired from informatics department of 
otorhinolaryngology department of our tertiary 
care center. The cases coded as “Sudden 
idiopathic hearing loss” according to 
International Classification of Diseases (ICD) 
were taken into account. Consequently, medical 
files of 56 female, and 82 male patients who 
were hospitalized, and treated with the 
diagnosis of sudden hearing loss were obtained. 
Fifteen female and 12 male patients whose 
laboratory data at admission could not be 
obtained were excluded from the study. Among 
the remaining cases, one female patient with 
chronic kidney disease, 2 patients (1 F and 1 M) 
diagnosed as schwannoma on MRI, and 2 
female patients with presumed diagnosis of 
fistula were not included in the study. Besides 
14 patients with diabetes (12 M and 2F) were 
also excluded from the study. As a result, a total 
of 92 patients (35 F and 57 M) were included in 
the study (Table 1). 
 
Table 1. Distribution of the patients included 
in, and excluded from the study based on 
causative factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ninety-two (35 F and 57 M) patients with 
similar age, and gender-distribution relative to 
the patient group who applied to our outpatient 
clinic within the first 3 months of the year 2014 
without any degree of hearing loss, and chronic 
disease and also underwent complete routine 
biochemical tests constituted the control group. 
In this study the following biochemical, and 
hematological parameters were evaluated: uric 
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acid, FBG, blood urea nitrogen (BUN), 
creatinine, hemoglobin (Hb), platelet, mean 
platelet volume (MPV), platelet distribution 
width (PDW), platelet count or plateletcrit 
(PTC), prothrombin time (PT), partial 
thromboplastin time (PTT), and international 
normalized ratio (INR). These hematologic 
parameters of the patient, and the control 
groups were compared, and any significant 
intergroup difference (if any) was evaluated. 
Average, and median uric acid values were 4.6 
mg/dl, and 4.5 mg/dl, respectively. Based on 
the median uric acid value, the patients were 
divided into 2 groups as those with uric acid 
levels of ≤ 4.5 mg/dL (n=47), and > 45 mg/dL 
(n=45). Pure-tone averages at the onset of the 
disease, and after the treatment, and also mean 
hearing gains of these groups were compared. 
In groups of patients formed based on the 
degree of the hearing loss, and audiometric 
pattern at admission, any significant difference 
(if any) as for mean uric acid levels, and a 
difference (if any) in the intragroup 
distributions of the groups constructed based on 
uric acid levels, and hearing gains were 
investigated. The patients were divided into 2 
groups based on pure-tone averages at 
admission as partial (<90 dB), and total hearing 
loss (≥90 dB). Based on the median value, the 
patients were divided into 2 groups as those 
with uric acid levels of ≤ 4.5 mg/dL (n=47), and 
> 45 mg/dL (n=45). Pure-tone averages at the 
onset of the disease, and after the treatment, and 
also mean hearing gains of these groups were 
compared. In groups of patients formed based 
on the degree of the hearing loss, types of 
audiograms recorded at admission, any 
significant difference (if any) as for mean uric 
acid levels, and a difference (if any) in the 
intragroup distributions of the groups 
constructed based on uric acid levels, and 
hearing gains were investigated. 
The patients were divided into 2 groups based 
on pure-tone averages at admission as partial 
(<90 dB), and total hearing loss (≥90 dB). 
When categorized in types of audiograms, 
upward-sloping, and flat-type audiograms 
which have been associated with better 
prognosis in literature studies [1] were included 
in Group 1, while flat type audiograms, and 
those indicating total hearing loss were 
categorized in Group 2. 
Treatment response was evaluated using Siegel 
classification [6], and the patients were divided 
into groups based on baseline pure tone 
averages as calculated in post-treatment 
audiometric tests as follows: hearing gain > 15 
dB (no improvement); ≥ 15 dB, and mean 
hearing acuity > 25 dB (partial improvement) 
pure-tone average in audiometry was ≥ 25 dB 
(total recovery).  
 
Statistical analysis 
For statistical analysis SPSS (Statistical 
Package for Social Sciences) for Windows 13.0 
program was used. In the comparison of data of 
the patient, and the control groups which 
demonstrated normal distribution as age, FBG, 
uric acid, platelet counts, MPV, and PTT 
values, Student –T test was used. For the 
comparison of variables with non-normal 
distribution such as BUN, creatinine, 
hemoglobin, platelet, PDW, INR, and PT 
values, Mann -Whitney U (MWU) test was 
employed. 
 
Results  
 
Demographic and biochemical comparisons 
Mean age of 35 female, and 57 male patients 
enrolled in the study was 43.6±16.84 (10-79) 
years. Mean age of the control group consisting 
of equal number of male and female patients 
was 42.8±16.5 (19-90) years. Any significant 
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intergroup difference was not detected 
regarding mean age of the patients (p=0.525). 
Mean uric acid levels of the patient, and control 
groups were 4.65 (n=92), and 4.63 mg/dL 
(n=92), respectively without any statistically 
significant intergroup difference (p=0.871). 
Mean uric acid levels of the female study 
participants in the patient, and the control 
groups were 4.00 (n=36), and 3.789 mg/dL 
(n=36), respectively without any statistically 
significant difference (p=0. 270). Mean uric 
acid levels of the male study participants of the 
patient, and the control groups were 5.06 mg/dL 
(n=56), and 5.16 mg/dL, respectively (n=56) 
without statistically significant intergroup 
difference (p=0,619). 
Among other parameters studied, creatinine, 
glucose, INR, and PT values were significantly 
higher in the patient group. BUN, Hb, platelet, 
MPV, plateletcrit, PDW, and PTT were not 
statistically significantly different between both 
groups. (Table 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic and biochemical data of the 
patient group  
Mean, and median uric acid levels of the patient 
group were 4.65, and 4.5 mg/dl, respectively. 
The patients were divided into two groups 
based on median uric acid value as Group 1 
(n=47; uric acid ≤ 4.5 mg/dL) and Group 2, 
(n=45; uric acid > 4.5 mg/dL). Among 
biochemical metabolites, and coagulation 
parameters Hb, BUN, and creatinine were 
significantly higher in Group 2 (p < 0.01), while 
other parameters did not differ significantly 
between groups. These two groups were 
compared as for treatment onset, and prognosis. 
In Group 1, 46, and in Group 2, 38 patients had 
their audiometric records. Pure-tone averages 
of the study participants estimated at admission 
were compared, and any statistically significant 
difference could not be found between groups 
(Group 1, 83. 23 dB, and Group 2, 74.11 dB) 
(p=0.072). Post-treatment audiometric test 
records were available for 46 individuals in 
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Group 1 and 36 participants in Group 2. 
Posttreatment pure-tone averages were 70.16 
dB in Group 1, and 54.58 dB in Group 2, with 
a statistically significant intergroup difference 
(p=0.034). Whereas mean hearing gain in 
Groups 1, and 2 were 12.98, and 20.78 dB, 
respectively, without any statistically 
significant intergroup difference (p=0.067). In 
summary, even a statistically significant 
difference could not be found, in the group with 
higher uric acid level milder hearing loss was 
detected at the onset of the disease with 
acquisition of higher hearing gain. Besides post 
treatment pure- tone averages were 
significantly better (Table 3). 
 
 
 
 
 
 
 
 
 
 
PTA: Pure-tone average. 
 
 
 
 
 
 
 
 
 
 
Hearing test records of 8 out of 92 patients at 
admission were not available, and the 
remaining 84 patients were divided into groups 
with partial, and total hearing loss (Group 1, 
n=53, and Group 2, n=29). Average uric acid 
levels of the patients with partial, and total 
hearing loss were 4.8 mg/dl, and 4.1 mg/dl, 
respectively with a statistically significant 
intergroup difference (p=0.008). In other words 
as uric acid levels increased, onset of sudden 
hearing loss was less aggressive. 
Audiometric records of 80 patients could be 
accessible. Patients with upward-sloping, and 
flat audiograms had a better prognosis (Group 
1, n=46) while patients with audiograms 
demonstrating a downward-sloping pattern and 
total loss were evaluated in Group 2 (n=34). 
Mean uric acid value of the group with upward-
sloping, and flat –type audiograms, and hence 
better prognosis was 4.7 mg/dL, while that of 
the patients with poor prognosis, who had 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
downward-sloping, and total loss type 
audiograms was 4.3 mg/dL, without any 
significant intergroup difference (p=0.149). 
The patients were divided into three groups 
based on their hearing gains they retrieved from 
the treatment using modified Siegel 
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classification [6]. The patients were divided 
into three groups. Mean hearing gain of the 
patients in Group 1 was less than 15 dB after 
treatment (no improvement) while of Group 2 
was less than 25 dB after treatment, and their 
hearing acuity was still less than 25 dB (partial 
improvement). In Group 3 mean hearing gain 
was above 25 dB (total improvement group). 
Posttreatment pure-tone averages of 82 out of 
92 patients were available. These patients were 
in the groups of no hearing gain (n=51; 62.2 %), 
partial gain (n=19; 23.2 %), and total gain 
(n=12; 14.6 %). When these groups were 
compared according to 2 groups divided based 
on uric acid values as ≤ 4.5 mg/dL, and > 4.5 
mg/dL p was equal to 0.098 according to chi-
square test, and distribution of the groups were 
statistically significantly different. However, 
when distributions into groups were analyzed 
numerically, the number of patients with 
hearing gain was higher in the group with 
increased uric acid levels, while lesser number 
of patients in this group had not achieve any 
hearing gain from the treatment (Table 4). 
 
Discussion 
In approximately 80 % of SHL patients an 
identifiable etiology is not found, and in its 
etiology mostly vascular theory has been 
emphasized [2]. Accordingly, hearing loss can 
arise from a sudden vascular bleeding in the 
cochlea [7], an occlusion caused by an embolus 
etc. [8], vasospasm [9] or alteration of blood 
viscosity [10]. 
In this study our target was essentially to 
analyze levels of uric acid whose role in 
vascular diseases, and oxidative stress have 
gained prominence in recent years in patients 
with SHL, compare its levels with those of the 
control group, and investigate its impact on 
prognosis. In our study, starting from vascular 
theory, a group of 92 patients with SHL were 
investigated as for uric acid levels, hematologic 
parameters which will effect blood viscosity, 
and coagulation, and biochemical variables 
which might exert an effect on plasma levels of 
uric acid, and these variables were compared 
with those of the control group  
In a study performed in the year 2012, a group 
of 147 patients with SHL was compared with a 
group of 103 control subjects with respect to 
similar parameters, and any significant 
intergroup difference could not be found 
regarding BUN, and creatinine values [11]. In 
our study we also investigated uric acid values, 
renal functions, and hence creatinine, and BUN 
values which reflect uric acid clearance. Mean 
creatinine value in the patient group was 0.01 
mg/dL higher than that of the control group that 
was statistically significant. Mean creatinine 
value in the patient group was 0.01 mg/dL 
higher than that of the control group which was 
statistically significant. Though higher mean 
BUN, and uric acid values were measured in the 
patient group, a significant difference was not 
found relative to the control group. 
In a study performed in 2014, all patients 
hospitalized with the diagnosis of SHL had 
undergone 75 gr oral glucose tolerance test, and 
more improved prognosis was detected in the 
normo-glycemic group relative to the group 
with impaired glucose tolerance test, and 
diabetes [12]. Even though diabetic patients 
were not included in our study, mean FBG level 
in the patient group was significantly higher 
when compared with the control group. These 
data may signify that though not at diabetic 
levels, higher fasting blood glucose (FBG) 
levels may be potentially effective factors in 
vascular etiopathogenesis of SHL.  
Myeloprolipherative disorders as essential 
thrombocytosis, and polycythemia can 
predispose to vascular pathologies by 
increasing blood viscosity. In a study where 147 
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SHL cases were compared as treatment –
responsive (n=102), and refractory (n=45) 
patients, hemoglobin levels were found to be 
significantly higher in the treatment-refractory 
group [11]. In our study, mean hemoglobin 
value in the control group was 0.1 mg /dL 
higher without any statistically significant 
intergroup difference.  
Platelets are the smallest cells in the peripheral 
blood, and they are responsible from the release 
of mediators involving in coagulation, 
inflammation, thrombosis, and atherosclerosis 
[13]. In a study performed in the year 2006, any 
significant difference could not be found 
between the control, and SHL groups regarding 
PT, PTT, and platelet counts [14]. We did not 
come across a significant difference between 
the patient, and the control groups when 
compared in terms of platelet counts, and 
plateletcrit values. Although any difference was 
not found between both groups as for PTT, 
INR, and PT -albeit within their normal limits- 
the levels of these parameters were significantly 
higher in the patient group, and higher levels of 
these parameters lead to a delay in coagulation 
with resultant increase in the risk of bleeding, 
and on the contrary a decrease in the risk of 
thrombus formation. 
Mean platelet volume (MPV) is the average of 
all platelet volumes, and it is used as a 
biomarker in the evaluation of production, and 
function of platelets. Large platelets are more 
active both from metabolic, and enzymatic 
aspects. Hence when compared with small 
platelets, they have a higher tendency to 
precipitate, and so an increased coagulation 
potential. In cases with vascular occlusion, 
acute, and chronic syndromes, MPV levels 
increase, but decrease in infections, 
autoimmune diseases or inflammatory 
conditions. In our study any significant 
difference was not found between the patient, 
and the control groups as for MPV, and PDW 
values. 
In studies performed in recent years the 
relationship between uric acid, and vascular 
injury of vascular, and renal tissues has been 
advocated. Pro-inflammatory, complement, 
platelet, and coagulation cascade activating, 
neutrophil, and macrophage stimulating, 
protease, and oxidant synthetizing effects of 
urate crystals are already known [4]. 
Deterioration of endothelial dysfunction has 
been detected in patients who were given uric 
acid preparations, and also an association 
between endogenous uric acid concentration 
and severity of endothelial dysfunction has 
been revealed [15]. Similarly, incidence rates of 
atherosclerosis, arteriosclerosis, 
glomerulosclerosis, vestibular ataxia, and 
renovascular pathologies increase in gout 
patients [16]. 
In the literature, higher uric acid levels have 
been reported to increase risks of coronary 
artery disease, and cerebrovascular disease. 
Increased uric acid levels have been thought to 
contribute to the atherosclerotic process by 
effecting endothelial functions, oxidative 
metabolism, adhesion, and aggregation of 
platelets [4]. As reported in the literature 
studies, after excluding other factors, each 1 
mg/dL increase in serum uric acid levels both 
in men, and women induces significant 
increases in cardiovascular, and coronary artery 
disease-related mortality rates [17]. Ding et al. 
advocated possible association between 
hyperuricemia, and thrombotic complications 
[18]. 
However, uric acid provides more than 50 % of 
antioxidant capacity of the blood, and exerts 
stabilizing effects on vitamins C, and E. 
Therefore, potential increase in uric acid levels 
has been suggestively associated with an 
antioxidant response to oxidative stress. It has 
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been thought that acute increase in uric acid 
levels is especially a response to oxidative 
stress, while its chronic increase is thought to 
be a risk factor for coronary, and cardiovascular 
diseases [19]. Even if its harmful pro-oxidant 
effect prevails over its beneficial antioxidant 
effect, its beneficial antioxidant effects seem to 
be more effective in the central nervous system 
[5]. In our study a significant difference was not 
detected in uric acid levels between the patient, 
and the control groups. In the literature we 
haven’t encountered any study which 
investigated the relationship between uric acid, 
and SHL. In accessible literature studies the 
effects of uric acid, and other risk factors on 
SHL has been investigated. In a study by 
Friedrich et al. the frequency of vascular risk 
factors as hyperuricemia, hyperglycemia, and 
cigarette smoking in 264 patients with SHL had 
been investigated, and the authors had detected 
higher rates of hyperuricemia, and 
hyperglycemia in patients with SHL relative to 
healthy population. In the same study, an 
inverse correlation was detected between 
recovery of hearing function, and number of 
risk factors [20]. In another study 163 patients 
with SHL were analyzed as for risk factors 
including hypertension, hyperlipidemia, 
smoking, hyperuricemia, and obesity, and 
significantly greater number of vascular risk 
factors were detected in the patient group 
relative to the control group [21]. 
In our study we evaluated the impact of uric 
acid levels on the onset, and prognosis of SHL, 
and 91 of 92 patients had uric acid levels within 
normal range, and only one patient had an uric 
acid level above 7.5 mg/dL (8,4 mg/dl). This 
patient applied with a hearing loss of 70 dB, and 
did not recover at all after treatment When the 
patient population were divided into groups 
with median uric acid levels of ≤ 4.5 mg/dl, and 
> 4.5 mg/dl, and pure-tone averages at 
admission were compared, pure-tone averages 
were found to be 83.23 dB, and 74.11 dB in 
Groups 1, and 2, respectively without any 
statistically significant intergroup difference 
(p=0.072). Posttreatment pure-tone averages of 
Groups 1, and 2 were 70.26, and 54.58 dB, 
respectively with a statistically significant 
intergroup difference (p=0.034). Hearing gains 
of Groups 1, and 2 were 12.98, and 20.78 dB 
without any statistically significant intergroup 
difference (p=0.067). In conclusion, although a 
statistically significant intergroup difference 
was not found, in the group with higher uric 
acid level at the onset of the disease hearing loss 
was less severe, and higher hearing gain was 
obtained. 
The patient population was divided into groups 
with partial, and total hearing loss (Group 1, 
n=53, and Group 2, n=29) with median serum 
uric acid levels as 4.8, and 4.1 mg/dL, 
respectively with a statistically significant 
intergroup difference (p=0.008). Similarly, the 
patients with better prognosis, and upward-
sloping and flat-type audiograms (n=46), and 
those with downward- sloping type , and total 
hearing loss (n=34) were compared as for mean 
serum uric acid levels (Group 1, 4.7 mg/dL, and 
Group 2, 4.3 mg/dL) without any significant 
intergroup difference (p=0.149). In other 
words, onset of sudden hearing loss was less 
aggressive as serum uric acid levels increased. 
Distribution of two groups constructed based 
on uric acid levels was separated into 3 groups 
as for hearing gains, and still any significant 
difference was not detected between these two 
groups (p=0.098). Though any intergroup 
difference was not detected, when distribution 
of patients was examined greater number of 
patients were seen in the group with lower uric 
acid levels, while in the group with higher uric 
acid levels the patients with partial, and 
complete recovery were more numerous. 
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As we already mentioned, most of the studies 
cited in the literature, have correlated uric acid 
levels, and sudden vascular diseases, worse 
disease prognosis, and thrombosis. However, in 
some studies deteriorated course of some 
neurological diseases such as multiple sclerosis 
[22], Parkinson’s disease [23], Alzheimer’s 
disease [24] in patients with lower uric acid 
levels have been reported [5]. Based on our 
data, the group with higher uric acid levels had 
better pre-and post-treatment pure-tone 
averages, hence treatment gain, and improved 
prognosis. Starting from the hypothesis that 
acute increase in uric acid levels occurs in 
response to oxidative stress, and uric acid 
ameliorates neuronal damage thanks to its 
antioxidant, and immunoregulatory effects [5, 
19] increased uric acid level can be suggested 
as a positive prognostic factor in SHL. In our 
study, scarce number of patients with 
supranormal uric acid levels, lack of any 
prominent difference between groups 
determined based on median uric acid value, 
unequal number of male, and female patients in 
groups precluded accurate interpretation of the 
results. In the years to come, if a larger-scale 
patient population with uric acid levels higher 
than normal range can be investigated, then it 
will be possible to achieve more accurate 
results.  
This is a retrospective study whose data set was 
constructed by screening the files of patients 
with SHL who applied to our clinic within the 
previous 6 years. Laboratory values of the 
patients with SHL were derived from the 
measurements made within 5 years, and for the 
control group, data were harvested among the 
measurements made for the patients applied for 
preoperative preparation for anesthesia within 
the previous year. Since medical files were 
screened to obtain data about symptoms, use of 
medication, and audiogram results, and 
physicians who prepared the files changed 
during 5 years, some omissions may be found 
in patient information. In the future, suspicious 
data stemming from various factors including 
concomitant diseases, and timing of laboratory 
tests can be minimized by designing 
prospective studies. 
 
Conclusion 
In conclusion, in this study we evaluated uric 
acid that is thought to be effective in endothelial 
dysfunction, at the onset, and progression of 
SHL, but we couldn’t find a significant 
difference between the patient, and the control 
groups as for uric acid levels. However, a 
significant difference was found between the 
patient, and the control groups with respect to 
other hematological, and biochemical 
parameters including creatinine, INR, and PT. 
Besides, we found that supported better disease 
onset, and prognosis in patients with higher uric 
acid levels. In conclusion, well-planned 
prospective studies with larger sample size 
should be performed to obtain more accurate 
data about vascular etiology of the sudden 
hearing loss, and the role of other biochemical 
parameters in the etiopathogenesis of SHL. 
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